Engineering influenza viral vectors

Bioengineered

Volumn 4, Issue 1, 2013, Pages

  Li, Junwei ^a   Arévalo, Maria T ^a   Zeng, Mingtao ^a  

^a Paul L Foster School of Medicine   (United States)

Author keywords

Gene delivery; Gene therapy; Influenza virus; Microrna delivery; Pseudo typed virus; Reverse genetics; Vaccine; Viral vector

Indexed keywords

BCG VACCINE; DNA DIRECTED RNA POLYMERASE; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 24; MICRORNA 124; RNA POLYMERASE; VACCINE; VIRUS PROTEIN; VIRUS RNA; VIRUS VECTOR;

ARTICLE; BACILLUS ANTHRACIS; HELPER VIRUS; IMMUNE RESPONSE; IMMUNIZATION; INFLUENZA VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR CLONING; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; REVERSE GENETICS; VIRAL GENE DELIVERY SYSTEM; VIRUS REPLICATION; ANIMAL; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMAN; INFLUENZA; MICRORNA DELIVERY; ORTHOMYXOVIRUS; PHYSIOLOGY; PSEUDO-TYPED VIRUS; REVIEW;

ORTHOMYXOVIRIDAE;

GENE DELIVERY; GENE THERAPY; INFLUENZA VIRUS; MICRORNA DELIVERY; PSEUDO-TYPED VIRUS; REVERSE GENETICS; VACCINE; VIRAL VECTOR;

ANIMALS; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE;

EID: 84877700482     PISSN: 19491018     EISSN: 19491026     Source Type: Journal    
DOI: 10.4161/bioe.21950     Document Type: Article

References (61)

1. Avilov SV, Moisy D, Munier S, Schraidt O, Naffakh N, Cusack S. Replication-competent influenza A virus that encodes a split-green fluorescent protein-tagged PB2 polymerase subunit allows live-cell imaging of the virus life cycle. J Virol 2012; 86:1433-48; PMID:22114331; http://dx.doi.org/10.1128/JVI.05820-11.
2. Chen W, Calvo PA, Malide D, Gibbs J, Schubert U, Bacik I, et al. A novel influenza A virus mitochondrial protein that induces cell death. Nat Med 2001; 7:1306- 12; PMID:11726970; http://dx.doi.org/10.1038/ nm1201-1306.
3. Gibbs JS, Malide D, Hornung F, Bennink JR, Yewdell JW. The influenza A virus PB1-F2 protein targets the inner mitochondrial membrane via a predicted basic amphipathic helix that disrupts mitochondrial function. J Virol 2003; 77:7214-24; PMID:12805420; http://dx.doi.org/10.1128/JVI.77.13.7214-7224.2003.
4. Wise HM, Foeglein A, Sun J, Dalton RM, Patel S, Howard W, et al. A complicated message: Identification of a novel PB1-related protein translated from influenza A virus segment 2 mRNA. J Virol 2009; 83:8021- 31; PMID:19494001; http://dx.doi.org/10.1128/ JVI.00826-09.
5. Skehel JJ, Hay AJ. Nucleotide sequences at the 5' termini of influenza virus RNAs and their transcripts. Nucleic Acids Res 1978; 5:1207-19; PMID:652519; http://dx.doi.org/10.1093/nar/5.4.1207.
6. Fujii Y, Goto H, Watanabe T, Yoshida T, Kawaoka Y. Selective incorporation of influenza virus RNA segments into virions. Proc Natl Acad Sci U S A 2003; 100:2002-7; PMID:12574509; http://dx.doi. org/10.1073/pnas.0437772100.
7. Watanabe T, Watanabe S, Noda T, Fujii Y, Kawaoka Y. Exploitation of nucleic acid packaging signals to generate a novel influenza virus-based vector stably expressing two foreign genes. J Virol 2003; 77:10575-83; PMID:12970442; http://dx.doi.org/10.1128/ JVI.77.19.10575-10583.2003.
8. Muramoto Y, Takada A, Fujii K, Noda T, Iwatsuki- Horimoto K, Watanabe S, et al. Hierarchy among viral RNA (vRNA) segments in their role in vRNA incorporation into influenza A virions. J Virol 2006; 80:2318- 25; PMID:16474138; http://dx.doi.org/10.1128/ JVI.80.5.2318-2325.2006.
9. Giannecchini S, Clausi V, Nosi D, Azzi A. Oligonucleotides derived from the packaging signal at the 5' end of the viral PB2 segment specifically inhibit influenza virus in vitro. Arch Virol 2009; 154:821-32; PMID:19370391; http://dx.doi.org/10.1007/s00705- 009-0380-2.
10. Hsu MT, Parvin JD, Gupta S, Krystal M, Palese P. Genomic RNAs of influenza viruses are held in a circular conformation in virions and in infected cells by a terminal panhandle. Proc Natl Acad Sci U S A 1987; 84:8140-4; PMID:2446318; http://dx.doi. org/10.1073/pnas.84.22.8140.
11. Flick R, Neumann G, Hoffmann E, Neumeier E, Hobom G. Promoter elements in the influenza vRNA terminal structure. RNA 1996; 2:1046-57; PMID:8849780.
12. Siegert W, Bauer G, Hofschneider PH. Direct evidence for messenger activity of influenza virion RNA. Proc Natl Acad Sci U S A 1973; 70:2960-3; PMID:4355376; http://dx.doi.org/10.1073/pnas.70.10.2960.
13. Glass SE, McGeoch D, Barry RD. Characterization of the mRNA of influenza virus. J Virol 1975; 16:1435- 43; PMID:1202243.
14. Bouloy M, Morgan MA, Shatkin AJ, Krug RM. Cap and internal nucleotides of reovirus mRNA primers are incorporated into influenza viral complementary RNA during transcription in vitro. J Virol 1979; 32:895-904; PMID:513205.
15. Parvin JD, Palese P, Honda A, Ishihama A, Krystal M. Promoter analysis of influenza virus RNA polymerase. J Virol 1989; 63:5142-52; PMID:2585601.
16. Luytjes W, Krystal M, Enami M, Parvin JD, Palese P. Amplification, expression, and packaging of foreign gene by influenza virus. Cell 1989; 59:1107-13; PMID:2598262; http://dx.doi.org/10.1016/0092- 8674(89)90766-6.
17. Barclay WS, Palese P. Influenza B viruses with sitespecific mutations introduced into the HA gene. J Virol 1995; 69:1275-9; PMID:7815505.
18. Horimoto T, Kawaoka Y. Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus. J Virol 1994; 68:3120-8; PMID:8151777.
19. Neumann G, Zobel A, Hobom G. RNA polymerase I-mediated expression of influenza viral RNA molecules. Virology 1994; 202:477-9; PMID:8009859; http://dx.doi.org/10.1006/viro.1994.1365.
20. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, et al. Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci U S A 1999; 96:9345-50; PMID:10430945; http://dx.doi. org/10.1073/pnas.96.16.9345.
21. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, García-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999; 73:9679-82; PMID:10516084.
22. Pekosz A, He B, Lamb RA. Reverse genetics of negative- strand RNA viruses: closing the circle. Proc Natl Acad Sci U S A 1999; 96:8804-6; PMID:10430844; http://dx.doi.org/10.1073/pnas.96.16.8804.
23. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97:6108-13; PMID:10801978; http://dx.doi.org/10.1073/pnas.100133697.
24. Neumann G, Fujii K, Kino Y, Kawaoka Y. An improved reverse genetics system for influenza A virus generation and its implications for vaccine production. Proc Natl Acad Sci U S A 2005; 102:16825-9; PMID:16267134; http://dx.doi.org/10.1073/pnas.0505587102.
25. Zhang X, Kong W, Ashraf S, Curtiss R 3rd. A oneplasmid system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine. J Virol 2009; 83:9296-303; PMID:19587040; http:// dx.doi.org/10.1128/JVI.00781-09.
26. Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, et al. Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment. J Virol 2005; 79:10672-7; PMID:16051859; http://dx.doi. org/10.1128/JVI.79.16.10672-10677.2005.
27. Rehwinkel J, Tan CP, Goubau D, Schulz O, Pichlmair A, Bier K, et al. RIG-I detects viral genomic RNA during negative-strand RNA virus infection. Cell 2010; 140:397-408; PMID:20144762; http://dx.doi. org/10.1016/j.cell.2010.01.020.
28. Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 1999; 9:237-44; PMID:10578119; http://dx.doi.org/10.1002/ (SICI)1099-1654(199910/12)9:4237::AIDRMV252 3.0.CO;2-G.
29. Horimoto T, Kawaoka Y. Designing vaccines for pandemic influenza. Curr Top Microbiol Immunol 2009; 333:165-76; PMID:19768405; http://dx.doi. org/10.1007/978-3-540-92165-3_8.
30. O'Neill E, Donis RO. Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. Curr Top Microbiol Immunol 2009; 333:83-108; PMID:19768401; http://dx.doi. org/10.1007/978-3-540-92165-3_4.
31. Johansson BE, Brett IC. Changing perspective on immunization against influenza. Vaccine 2007; 25:3062-5; PMID:17276554; http://dx.doi. org/10.1016/j.vaccine.2007.01.030.
32. Merkulov VA, Lebedev VN, Plekhanova TM, Maksimov VA, Korovkin SA, Mironov AN. Using reverse genetics method for developing recombinant strains of influenza viruses acceptable for use as live attenuated vaccines. Zh Mikrobiol Epidemiol Immunobiol 2009; 111-7; PMID:19462520.
33. Larsen DL, Karasin A, Zuckermann F, Olsen CW. Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Vet Microbiol 2000; 74:117-31; PMID:10799784; http://dx.doi. org/10.1016/S0378-1135(00)00172-3.
34. Muster T, Guinea R, Trkola A, Purtscher M, Klima A, Steindl F, et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994; 68:4031-4; PMID:7514684.
35. Muster T, Ferko B, Klima A, Purtscher M, Trkola A, Schulz P, et al. Mucosal model of immunization against human immunodeficiency virus type 1 with a chimeric influenza virus. J Virol 1995; 69:6678-86; PMID:7474077.
36. Hatziioannou T, Delahaye E, Martin F, Russell SJ, Cosset FL. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 1999; 10:1533-44; PMID:10395378; http://dx.doi. org/10.1089/10430349950017860.
37. Langley WA, Bradley KC, Li ZN, Smith ME, Schnell MJ, Steinhauer DA. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways. J Virol 2010; 84:8300-7; PMID:20504926; http://dx.doi.org/10.1128/ JVI.00183-10.
38. Hai R, García-Sastre A, Swayne DE, Palese P. A reassortment- incompetent live attenuated influenza virus vaccine for protection against pandemic virus strains. J Virol 2011; 85:6832-43; PMID:21543486; http:// dx.doi.org/10.1128/JVI.00609-11.
39. Castrucci MR, Hou S, Doherty PC, Kawaoka Y. Protection against lethal lymphocytic choriomeningitis virus (LCMV) infection by immunization of mice with an influenza virus containing an LCMV epitope recognized by cytotoxic T lymphocytes. J Virol 1994; 68:3486-90; PMID:7514676.
40. Mishin VP, Nedyalkova MS, Hayden FG, Gubareva LV. Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model. Vaccine 2005; 23:2922-7; PMID:15780741; http://dx.doi.org/10.1016/j.vaccine. 2004.11.058.
41. Efferson CL, Schickli J, Ko BK, Kawano K, Mouzi S, Palese P, et al. Activation of tumor antigen-specific cytotoxic T lymphocytes (CTLs) by human dendritic cells infected with an attenuated influenza A virus expressing a CTL epitope derived from the HER-2/neu proto-oncogene. J Virol 2003; 77:7411-24; PMID:12805440; http://dx.doi.org/10.1128/ JVI.77.13.7411-7424.2003.
42. Garulli B, Kawaoka Y, Castrucci MR. Mucosal and systemic immune responses to a human immunodeficiency virus type 1 epitope induced upon vaginal infection with a recombinant influenza A virus. J Virol 2004; 78:1020-5; PMID:14694134; http://dx.doi. org/10.1128/JVI.78.2.1020-1025.2004.
43. Li F, Feng L, Pan W, Dong Z, Li C, Sun C, et al. Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segment. J Virol 2010; 84:12075-81; PMID:20826692; http://dx.doi.org/10.1128/ JVI.00046-10.
44. Manicassamy B, Manicassamy S, Belicha-Villanueva A, Pisanelli G, Pulendran B, García-Sastre A. Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A 2010; 107:11531-6; PMID:20534532; http://dx.doi. org/10.1073/pnas.0914994107.
45. Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, Wolkerstorfer A, et al. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology 2004; 324:67-73; PMID:15183054; http://dx.doi. org/10.1016/j.virol.2004.03.035.
46. Robb NC, Smith M, Vreede FT, Fodor E. NS2/ NEP protein regulates transcription and replication of the influenza virus RNA genome. J Gen Virol 2009; 90:1398-407; PMID:19264657; http://dx.doi. org/10.1099/vir.0.009639-0.
47. García-Sastre A, Muster T, Barclay WS, Percy N, Palese P. Use of a mammalian internal ribosomal entry site element for expression of a foreign protein by a transfectant influenza virus. J Virol 1994; 68:6254-61; PMID:8083965.
48. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, Vanin EF, et al. Correction of multigene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 2004; 22:589-94; PMID:15064769; http://dx.doi. org/10.1038/nbt957.
49. Trichas G, Begbie J, Srinivas S. Use of the viral 2A peptide for bicistronic expression in transgenic mice. BMC Biol 2008; 6:40; PMID:18793381; http:// dx.doi.org/10.1186/1741-7007-6-40.
50. Talon J, Salvatore M, O'Neill RE, Nakaya Y, Zheng H, Muster T, et al. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc Natl Acad Sci U S A 2000; 97:4309-14; PMID:10725408; http://dx.doi.org/10.1073/pnas.070525997.
51. Ferko B, Stasakova J, Sereinig S, Romanova J, Katinger D, Niebler B, et al. Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol 2001; 75:8899-908; PMID:11533153; http://dx.doi.org/10.1128/JVI.75.19.8899-8908.2001.
52. Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol 2006; 80:11621-7; PMID:16971432; http://dx.doi. org/10.1128/JVI.01645-06.
53. Wolschek M, Samm E, Seper H, Sturlan S, Kuznetsova I, Schwager C, et al. Establishment of a chimeric, replication-deficient influenza A virus vector by modulation of splicing efficiency. J Virol 2011; 85:2469-73; PMID:21177819; http://dx.doi.org/10.1128/ JVI.01650-10.
54. Li Y, Lu X, Li J, Bérubé N, Giest KL, Liu Q, et al. Genetically engineered, biarsenically labeled influenza virus allows visualization of viral NS1 protein in living cells. J Virol 2010; 84:7204-13; PMID:20463066; http://dx.doi.org/10.1128/JVI.00203-10.
55. Takasuka N, Enami M, Itamura S, Takemori T. Intranasal inoculation of a recombinant influenza virus containing exogenous nucleotides in the NS segment induces mucosal immune response against the exogenous gene product in mice. Vaccine 2002; 20:1579-85; PMID:11858865; http://dx.doi.org/10.1016/S0264-410X(01)00491-1.
56. Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, et al. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb) 2006; 86:236-46; PMID:16677861; http://dx.doi.org/10.1016/j.tube.2006.01.010.
57. Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, et al. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol 2006; 13:898-904; PMID:16893990; http://dx.doi.org/10.1128/CVI.00056-06.
58. Gao Q, Lowen AC, Wang TT, Palese P. A nine-segment influenza a virus carrying subtype H1 and H3 hemagglutinins. J Virol 2010; 84:8062-71; PMID:20519387; http://dx.doi.org/10.1128/JVI.00722-10.
59. Martínez-Sobrido L, Cadagan R, Steel J, Basler CF, Palese P, Moran TM, et al. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J Virol 2010; 84:2157-63; PMID:19939917; http://dx.doi.org/10.1128/JVI.01433-09.
60. Perez JT, Pham AM, Lorini MH, Chua MA, Steel J, tenOever BR. MicroRNA-mediated species-specific attenuation of influenza A virus. Nat Biotechnol 2009; 27:572-6; PMID:19483680; http://dx.doi.org/10.1038/nbt.1542.
61. Varble A, Chua MA, Perez JT, Manicassamy B, García- Sastre A, tenOever BR. Engineered RNA viral synthesis of microRNAs. Proc Natl Acad Sci U S A 2010; 107:11519-24; PMID:20534531; http://dx.doi.org/10.1073/pnas.1003115107.